<DOC>
	<DOCNO>NCT02826863</DOCNO>
	<brief_summary>This multicenter , double-blind , parallel-group , placebo-controlled , study assess efficacy , safety , pharmacokinetics ZX008 use adjunctive therapy pediatric young adult subject Dravet syndrome . Subjects qualify study randomize ( 1:1:1 ) double-blind manner receive 1 2 dos ZX008 placebo . All subject titrate randomize dose 14-day Titration Period . Following titration , subject continue treatment randomly assign dose 12-week Maintenance Period . Total treatment time begin Titration Period end Maintenance Period 14 week .</brief_summary>
	<brief_title>A Trial Two Fixed Doses ZX008 ( Fenfluramine HCl ) Adjunctive Therapy Children Young Adults With Dravet Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Epilepsies , Myoclonic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Fenfluramine</mesh_term>
	<criteria>Key Inclusion Criteria Male nonpregnant , nonlactating female , age 2 18 year , inclusive day Screening Visit . Clinical diagnosis Dravet syndrome , convulsive seizure completely control current antiepileptic drug . Must minimum # convulsive seizure per 4week period past 12 week prior screen . All medication intervention epilepsy ( include KD VNS ) must stable least 4 week prior screen expect remain stable throughout study . Parent/caregiver willing able compliant diary completion , visit schedule study drug accountability . Key Exclusion Criteria Pulmonary arterial hypertension . Current past history cardiovascular cerebrovascular disease , cardiac valvulopathy , myocardial infarction stroke . Current past history glaucoma . Moderate severe hepatic impairment Receiving concomitant therapy : centrallyacting anorectic agent ; monoamineoxidase inhibitor ; medication act via serotonin include serotonin reuptake inhibitor ; atomoxetine , centrallyacting noradrenergic agonist ; cyproheptadine , and/or CYP 2D6/3A4/2B6 inhibitors/substrates . Currently take carbamazepine , oxcarbamazepine , eslicarbazepine , phenobarbital , phenytoin , take within past 30 day . Subject unwilling refrain large daily serving grapefruit and/or Seville orange , juice begin Baseline Period throughout study . A clinically significant condition , clinically relevant symptom clinically significant illness 4 week prior Screening Visit , epilepsy , would negatively impact study participation , collection study data , pose risk subject . Currently receive investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>seizure</keyword>
	<keyword>tonic-atonic</keyword>
	<keyword>epilepsy</keyword>
	<keyword>myoclonic</keyword>
	<keyword>encephalopathy</keyword>
</DOC>